Cargando…
The NeuroAiD Safe Treatment (NeST) Registry: a protocol
INTRODUCTION: NeuroAiD (MLC601, MLC901), a combination of natural products, has been shown to be safe and to aid neurological recovery after brain injuries. The NeuroAiD Safe Treatment (NeST) Registry aims to assess its use and safety in the real-world setting. METHODS AND ANALYSIS: The NeST Registr...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4654343/ https://www.ncbi.nlm.nih.gov/pubmed/26567259 http://dx.doi.org/10.1136/bmjopen-2015-009866 |
_version_ | 1782402042522763264 |
---|---|
author | Venketasubramanian, Narayanaswamy Kumar, Ramesh Soertidewi, Lyna Abu Bakar, Azizi Laik, Carine Gan, Robert |
author_facet | Venketasubramanian, Narayanaswamy Kumar, Ramesh Soertidewi, Lyna Abu Bakar, Azizi Laik, Carine Gan, Robert |
author_sort | Venketasubramanian, Narayanaswamy |
collection | PubMed |
description | INTRODUCTION: NeuroAiD (MLC601, MLC901), a combination of natural products, has been shown to be safe and to aid neurological recovery after brain injuries. The NeuroAiD Safe Treatment (NeST) Registry aims to assess its use and safety in the real-world setting. METHODS AND ANALYSIS: The NeST Registry is designed as a product registry that would provide information on the use and safety of NeuroAiD in clinical practice. An online NeST Registry was set up to allow easy entry and retrieval of essential information including demographics, medical conditions, clinical assessments of neurological, functional and cognitive state, compliance, concomitant medications, and side effects, if any, among patients on NeuroAiD. Patients who are taking or have been prescribed NeuroAiD may be included. Participation is voluntary. Data collected are similar to information obtained during standard care and are prospectively entered by the participating physicians at baseline (before initialisation of NeuroAiD) and during subsequent visits. The primary outcome assessed is safety (ie, non-serious and serious adverse event), while compliance and neurological status over time are secondary outcomes. The in-person follow-up assessments are timed with clinical appointments. Anonymised data will be extracted and collectively analysed. Initial target sample size for the registry is 2000. Analysis will be performed after every 500 participants entered with completed follow-up information. ETHICS AND DISSEMINATION: Doctors who prescribe NeuroAiD will be introduced to the registry by local partners. The central coordinator of the registry will discuss the protocol and requirements for implementation with doctors who show interest. Currently, the registry has been approved by the Ethics Committees of Universiti Kebangsaan Malaysia (Malaysia) and National Brain Center (Indonesia). In addition, for other countries, Ethics Committee approval will be obtained in accordance with local requirements. TRIAL REGISTRATION NUMBER: NCT02536079. |
format | Online Article Text |
id | pubmed-4654343 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-46543432015-12-02 The NeuroAiD Safe Treatment (NeST) Registry: a protocol Venketasubramanian, Narayanaswamy Kumar, Ramesh Soertidewi, Lyna Abu Bakar, Azizi Laik, Carine Gan, Robert BMJ Open Neurology INTRODUCTION: NeuroAiD (MLC601, MLC901), a combination of natural products, has been shown to be safe and to aid neurological recovery after brain injuries. The NeuroAiD Safe Treatment (NeST) Registry aims to assess its use and safety in the real-world setting. METHODS AND ANALYSIS: The NeST Registry is designed as a product registry that would provide information on the use and safety of NeuroAiD in clinical practice. An online NeST Registry was set up to allow easy entry and retrieval of essential information including demographics, medical conditions, clinical assessments of neurological, functional and cognitive state, compliance, concomitant medications, and side effects, if any, among patients on NeuroAiD. Patients who are taking or have been prescribed NeuroAiD may be included. Participation is voluntary. Data collected are similar to information obtained during standard care and are prospectively entered by the participating physicians at baseline (before initialisation of NeuroAiD) and during subsequent visits. The primary outcome assessed is safety (ie, non-serious and serious adverse event), while compliance and neurological status over time are secondary outcomes. The in-person follow-up assessments are timed with clinical appointments. Anonymised data will be extracted and collectively analysed. Initial target sample size for the registry is 2000. Analysis will be performed after every 500 participants entered with completed follow-up information. ETHICS AND DISSEMINATION: Doctors who prescribe NeuroAiD will be introduced to the registry by local partners. The central coordinator of the registry will discuss the protocol and requirements for implementation with doctors who show interest. Currently, the registry has been approved by the Ethics Committees of Universiti Kebangsaan Malaysia (Malaysia) and National Brain Center (Indonesia). In addition, for other countries, Ethics Committee approval will be obtained in accordance with local requirements. TRIAL REGISTRATION NUMBER: NCT02536079. BMJ Publishing Group 2015-11-13 /pmc/articles/PMC4654343/ /pubmed/26567259 http://dx.doi.org/10.1136/bmjopen-2015-009866 Text en Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/ This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
spellingShingle | Neurology Venketasubramanian, Narayanaswamy Kumar, Ramesh Soertidewi, Lyna Abu Bakar, Azizi Laik, Carine Gan, Robert The NeuroAiD Safe Treatment (NeST) Registry: a protocol |
title | The NeuroAiD Safe Treatment (NeST) Registry: a protocol |
title_full | The NeuroAiD Safe Treatment (NeST) Registry: a protocol |
title_fullStr | The NeuroAiD Safe Treatment (NeST) Registry: a protocol |
title_full_unstemmed | The NeuroAiD Safe Treatment (NeST) Registry: a protocol |
title_short | The NeuroAiD Safe Treatment (NeST) Registry: a protocol |
title_sort | neuroaid safe treatment (nest) registry: a protocol |
topic | Neurology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4654343/ https://www.ncbi.nlm.nih.gov/pubmed/26567259 http://dx.doi.org/10.1136/bmjopen-2015-009866 |
work_keys_str_mv | AT venketasubramaniannarayanaswamy theneuroaidsafetreatmentnestregistryaprotocol AT kumarramesh theneuroaidsafetreatmentnestregistryaprotocol AT soertidewilyna theneuroaidsafetreatmentnestregistryaprotocol AT abubakarazizi theneuroaidsafetreatmentnestregistryaprotocol AT laikcarine theneuroaidsafetreatmentnestregistryaprotocol AT ganrobert theneuroaidsafetreatmentnestregistryaprotocol AT venketasubramaniannarayanaswamy neuroaidsafetreatmentnestregistryaprotocol AT kumarramesh neuroaidsafetreatmentnestregistryaprotocol AT soertidewilyna neuroaidsafetreatmentnestregistryaprotocol AT abubakarazizi neuroaidsafetreatmentnestregistryaprotocol AT laikcarine neuroaidsafetreatmentnestregistryaprotocol AT ganrobert neuroaidsafetreatmentnestregistryaprotocol |